Healthcare / BiotechnologyNasdaqGS
$1.80
-0.10 (-5.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-122.4M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$242M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-391.4%
↓Gross Margin
N/A
•Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-101.7M · FCF $-84.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | — | — | — | — | — | $0.00 | $1.2M | $4.8M | $2.1M |
| Net Income | $-101.7M | $-101.7M | $-134.8M | $-160.8M | $-123.5M | $-83.5M | $-45.7M | $-19.2M | $-13.7M |
| EBITDA | $-99.4M | $-99.4M | $-132.2M | $-158.4M | $-122.8M | $-83.5M | $-43.5M | $-18.8M | $-13.3M |
| EPS | — | — | -2.58 | -3.74 | -3.03 | -2.07 | -2.76 | — | — |
| Operating Margin | — | — | — | — | — | — | -3694.0% | -400.0% | -662.0% |
| Net Margin | — | — | — | — | — | — | -3869.7% | -401.2% | -664.3% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.38 | 0.38 | 0.09 | 0.05 | 0.04 | — | — | -0.08 | — |
| Current Ratio | 7.21 | 7.21 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-84.4M | $-84.4M | $-122.4M | $-131.6M | $-90.7M | $-68.8M | $-38.3M | $-14.6M | $-13.8M |
| Returns | |||||||||
| ROE | -391.4% | -391.4% | -118.7% | -84.8% | -46.9% | -23.0% | -10.6% | 27.2% | 26.5% |
| Valuation | |||||||||
| P/B | 3.77 | 3.77 | 0.83 | 2.85 | 1.69 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | — | — | — | — | — | -100.0% | -75.4% | 132.0% | — |
| EPS Growth | — | — | 31.0% | -23.4% | — | 25.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+270.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.58 → n/d
Residual
+270.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.